Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients

NCT01602198 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT01602198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01602198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients
Lead sponsor
The Cleveland Clinic
Phase
Not applicable
Overall status
Terminated
Start date
June 30, 2011
Completion date
January 31, 2013
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive disorder, mild cognitive impairment